Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
#YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=106390
Shares in Novo Nordisk Plunge 14% as Next-Generation Obesity Drug Falls Short of Expectations
Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
Shares of SK Inc. and Peptron Inc. surged after Eli Lilly announced plans to establish a production base for its obesity drug Mounjaro in South Korea, with both companies set to play key roles in manufacturing and supply.
#YonhapInfomax #EliLilly #Mounjaro #SKInc #Peptron #ObesityDrug #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=93013
Expectations Rise for Mounjaro Obesity Drug Production—SK and Peptron Shares Surge
Shares of SK Inc. and Peptron Inc. surged after Eli Lilly announced plans to establish a production base for its obesity drug Mounjaro in South Korea, with both companies set to play key roles in manufacturing and supply.
Hanmi Pharmaceutical Shares Surge 26% on Positive Obesity Drug Trial Results—Analysts Caution Overheated R&D Expectations
Hanmi Pharmaceutical shares surged 26% after positive Phase 3 obesity drug results, boosting R&D optimism, though analysts warn of overheating amid upcoming clinical milestones.
Citi Upgrades BioAge Labs to 'Buy' on Obesity Drug Pipeline
Citi Group has upgraded BioAge Labs to 'Buy' and doubled its price target, citing strong prospects for its obesity drug pipeline and upcoming data releases.
Viking Therapeutics shares plunged 42% after interim Phase 2 trial data for its oral obesity drug VK2735 revealed high dropout rates and side effects, disappointing investors despite comparable weight loss efficacy to competitors.
#YonhapInfomax #VikingTherapeutics #ObesityDrug #ClinicalTrial #DropoutRate #WeightLossEfficacy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=77793
Viking Therapeutics Plunges 42% on Disappointing Obesity Drug Trial Results
Viking Therapeutics shares plunged 42% after interim Phase 2 trial data for its oral obesity drug VK2735 revealed high dropout rates and side effects, disappointing investors despite comparable weight loss efficacy to competitors.
Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.
#YonhapInfomax #NovoNordisk #EliLilly #ObesityDrug #CagriSema #StockDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=68945
Novo Nordisk Shares Plunge 5% on Obesity Drug Competition Concerns
Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.
GLP-1 Obesity Drug Could Succeed... US Pharma Terns' Stock Expected to Rise 5-fold
US biotech firm Terns Pharmaceuticals sees potential 5-fold stock increase on promising obesity drug developments and analyst optimism
In an election year when both presidential candidates are tapping into anger about
#DrugPrices, both
#ObesityDrug makers and
#PBMs are feeling INTENSE heat.
https://conscienhealth.org/2024/09/obesity-drug-makers-and-pbms-feel-the-heat-of-pricing-scrutiny/
Obesity Drug Makers and PBMs Feel the Heat of Pricing Scrutiny - ConscienHealth
Both PBMs and obesity drug makers are feeling hot scrutiny over drug pricing. Presidential election politics tap into a real human concern.
Obesity drug helps teens lose weight, study finds
A drug called semaglutide, which is approved for adults with obesity or overweight, also helps adolescents shed pounds and have healthier hearts, according to a new study published today in the New England Journal of Medicine and presented at Obesity Week 2022.
Yonhap Infomax News
ConscienHealth
Phys.org